125 related articles for article (PubMed ID: 20446892)
1. Scleroderma induced by paclitaxel.
Pedersen JV; Jensen S; Krarup-Hansen A; Riis L
Acta Oncol; 2010 Aug; 49(6):866-8. PubMed ID: 20446892
[No Abstract] [Full Text] [Related]
2. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
Muñoz-Casares FC; Rufián S; Arjona-Sánchez Á; Rubio MJ; Díaz R; Casado Á; Naranjo Á; Díaz-Iglesias CJ; Ortega R; Muñoz-Villanueva MC; Muntané J; Aranda E
Cancer Chemother Pharmacol; 2011 Jul; 68(1):267-74. PubMed ID: 21499894
[TBL] [Abstract][Full Text] [Related]
3. Localized toxic erythema of chemotherapy during treatment with paclitaxel.
Spicknall KE; Mutasim DF
Int J Dermatol; 2014 Jan; 53(1):e3-5. PubMed ID: 23451872
[No Abstract] [Full Text] [Related]
4. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
; Markman M; Blessing J; Rubin SC; Connor J; Hanjani P; Waggoner S
Gynecol Oncol; 2006 Jun; 101(3):436-40. PubMed ID: 16325893
[TBL] [Abstract][Full Text] [Related]
6. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
7. [Myocardial infarction after paclitaxel use].
Mersin N; Boulbair F; Davani S; Hehn M; Kantelip JP
Therapie; 2003; 58(5):467-9. PubMed ID: 14682199
[No Abstract] [Full Text] [Related]
8. [Safety of intraperitoneal chemotherapy with paclitaxel in gastric cancer patients with peritoneal dissemination].
Fujitani K; Hirao M; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1855-7. PubMed ID: 15553738
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
10. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
De Angelis R; Bugatti L; Cerioni A; Del Medico P; Filosa G
Clin Rheumatol; 2003 Feb; 22(1):49-52. PubMed ID: 12605319
[TBL] [Abstract][Full Text] [Related]
11. Cardiac dysfunction in cancer patients receiving paclitaxel.
Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA
Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974
[No Abstract] [Full Text] [Related]
12. [Morphea type plaques induced by paclitaxel].
Torregrosa JL; Fernández M; Garcías J; Pérez A
Med Clin (Barc); 2014 May; 142(9):424-5. PubMed ID: 24018254
[No Abstract] [Full Text] [Related]
13. Scleroderma-like cutaneous lesions induced by paclitaxel and carboplatin for ovarian carcinoma, not a single course of carboplatin, but re-induced and worsened by previously administrated paclitaxel.
Konishi Y; Sato H; Sato N; Fujimoto T; Fukuda J; Tanaka T
J Obstet Gynaecol Res; 2010 Jun; 36(3):693-6. PubMed ID: 20598060
[TBL] [Abstract][Full Text] [Related]
14. Histopathological improvement of scleroderma induced by paclitaxel in a patient with breast cancer.
Ohashi A; Minagawa A; Ashida A; Koga H; Uhara H; Okuyama R
J Dermatol; 2015 Dec; 42(12):1198-9. PubMed ID: 26333146
[No Abstract] [Full Text] [Related]
15. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic ascites: taxol-induced hypersensitivity?
Kobayashi TK; Muramatsu M; Ueda M; Nishino T; Bamba M; Urabe M; Moritani S
Cytopathology; 2004 Jun; 15(3):171-2. PubMed ID: 15165278
[No Abstract] [Full Text] [Related]
17. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
19. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
de Bree E; Rosing H; Filis D; Romanos J; Melisssourgaki M; Daskalakis M; Pilatou M; Sanidas E; Taflampas P; Kalbakis K; Beijnen JH; Tsiftsis DD
Ann Surg Oncol; 2008 Apr; 15(4):1183-92. PubMed ID: 18239973
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced exacerbation of glomus tumour pain.
Daghir A; Anand P; Gabra H; Elliot D
J Hand Surg Br; 2006 Dec; 31(6):692. PubMed ID: 16766103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
